Author(s)
Santos H1, Laires PA2, Garcia S3, Nero P4, Pestana J5, Martins-Martinho J6, Silva AB7, Rodrigues J8, Sequeira G9, Costa E10, Santos FC11, Furtado C12, Santos B13, Raposo A14, Saraiva L15, Samões B16, Barcelos F1, Santos MJ5, Tavares-Costa J17
1Instituto Português de Reumatologia, Lisbon, Portugal, 2HE&OR, Novartis Farma, Produtos Farmacêuticos SA, Porto Salvo, Portugal, 3Rheumatology Departent, Hospital São João Hospital, Oporto, Portugal, 4Hospital CUF Descobertas, Lisbon, Portugal, 5Hospital Garcia de Orta, Almada, Portugal, 6Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal, 7Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, 8Unidade de Saúde Local do Alto Minho, Hospital Conde Bertiandos, Ponte de Lima, Portugal, 9Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, 10Hospital de Braga, Braga, Portugal, 11Unidade de Saúde Local da Guarda, Guarda, Portugal, 12Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Portugal, 13Hospital do Baixo Vouga, Aveiro, Portugal, 14Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, 15Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 16Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal, 17ULSAM, Ponte de Lima, Portugal
OBJECTIVES: To describe baseline characteristics of ankylosing spondylitis (AS) patients who initiated secukinumab in Portugal. METHODS: This registry-based analysis included all Portuguese patients diagnosed with AS, aged ≥ 18 years, registered in the rheumatic diseases Portuguese registry - Reuma.pt (Jan 2018-May 2020). We collected and analyzed patients’ characteristics at baseline including demographic variables, disease scores and previous treatments. RESULTS: We identified a total of 104 AS patients treated with secukinumab. In 24.0%, secukinumab was the first biologic (naïve) and 76.0% was non-naïve (37.5% had one previous biologic and 38.5% had two or more). Overall, 51.9% were male and mean age was 46.5(SD:11.7) years, but naïve patients were younger [naïve 42.0(10.7) years, non-naïve 48.0(11.7) years; p=0.022]. Mean age at diagnosis was 34.5(9.8) years and mean delay to diagnosis was 5.8(6.8) years, with no statistical differences between the two groups. Among non-naïve, adalimumab was the most used first biologic (35.4%). The higher dosage of secukinumab (300mg) was given in 10.6% of AS patients. Mean disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index was 6.0(2.2), while the mean Ankylosing Spondylitis Disease Activity Score was 3.5(1.0); function measured by the Bath Ankylosing Spondylitis Functional Index was 6.3(2.2). None of these scores was statistically different between naïve versus non-naïve patients. Mean EQ-5D, was 0.28(0.26), which is almost a third of the average score of the Portuguese Population (0.76). CONCLUSIONS: Our results provide insightful information about AS patients initiating secukinumab in a real-life setting, demonstrating some differences in baseline characteristics comparing to pivotal trials, namely fewer naive patients, but approximately the same levels of disease activity. Baseline quality of life is highly impaired, highlighting the importance of providing patients with an effective treatment.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PMS10
Topic
Clinical Outcomes, Patient-Centered Research
Topic Subcategory
Clinician Reported Outcomes, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Musculoskeletal Disorders
